Navigation Links
The Hepatitis C Virus Drug Market Will More Than Triple by 2014 but, Thereafter, the Market Will Decline Substantially Through 2019 Due to Decreasing Disease Prevalence and the High Efficacy of New Treatments
Date:11/16/2010

BURLINGTON, Mass., Nov. 16, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to the launch of several novel agents, the hepatitis C virus (HCV) drug market will more than triple from approximately $2 billion in 2009 to nearly $7.5 billion in 2014 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Thereafter, the market will substantially decrease to $4.6 billion in 2019 due to decreasing prevalence of the disease and the high efficacy of new treatment regimens.

The Pharmacor 2010 findings from the topic entitled Hepatitis C Virus reveal that the standard of care for the indication will change significantly with the introduction of new classes of HCV-specific antiviral agents, such as protease inhibitors and polymerase inhibitors. Compounds from these new classes will initially be added to the backbone of currently used agents, forming triple or quadruple treatment regimens that are expected to be more efficacious than the current standard of care -- peg-IFN/ribavirin.

"Although complete elimination of peg-IFNs and ribavirin agents is highly desirable owing to their side effects, this change is unlikely to occur over the next decade," said Decision Resources Analyst Alexandra Makarova, M.D., Ph.D. "However, decreased treatment durations resulting from the addition of new antivirals could increase the tolerability of treatment regimens. The launch of novel HCV-specific agents will increase the size of the drug-treated population, owing mainly to re-treatment of prior non-responders as well as increased referral and drug-treatment rates."

The current standard of care for HCV -- often a nearly year-long treatment -- cures only about half of patients and is associated with severe side effects. Although the incidence of HCV has declined dramatically after the introduction of prevention measures such as b
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Drug in New Hepatitis C Clinical Trial
3. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
4. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
5. Dynavaxs HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
6. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
7. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
8. Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
9. R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
10. Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies
11. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)...  According to data released today by the Centers ... Medicare Part D premium is expected to remain stable ... projected, the Pharmaceutical Care Management Association (PCMA) said. ... a bright spot in American health care. By offering ... using cutting edge, cost-saving tools like pharmacy networks and ...
(Date:7/31/2014)... Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ), a ... today reported its financial results for the quarter ended June ... of 2014 to the same period of 2013: , ... , t:slim Pump shipments grew 64 percent to 2,235 ... ended June 30, 2014 to the same period of 2013: ...
(Date:7/31/2014)... July 31, 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ... on its pipeline and new product development efforts. In ... initiate a Phase 2a study of AZ-002 (Staccato ... the management of patients with acute repetitive seizures. ... -based product candidates for development - AZ-008 and ...
Breaking Medicine Technology:Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 5Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 6Alexza Provides Pipeline Update 2Alexza Provides Pipeline Update 3Alexza Provides Pipeline Update 4Alexza Provides Pipeline Update 5Alexza Provides Pipeline Update 6
... Pharmaceuticals, Inc. (NYSE: WPI ), today confirmed ... of Delaware has ruled that Watson,s generic version of ... No. 6,264,981 (the ,981 Patent).  The Company said that ... all available options, including an appeal. ...
... 25, 2011 Approximately five percent of prescriptions submitted ... a 30-day period during 2009 included a "dispense as ... patients demand the dispensing of a specific brand-name drug ... care system up to $7.7 billion annually, according to ...
Cached Medicine Technology:Watson Confirms District Court Ruling in Generic Fentora® Patent Suit 2CVS Caremark Research Finds "Dispense as Written" Prescriptions May Add $7.7 Billion to Annual Health Care Costs 2CVS Caremark Research Finds "Dispense as Written" Prescriptions May Add $7.7 Billion to Annual Health Care Costs 3
(Date:8/1/2014)... use among young people has spiked, with 29.3 percent ... at least once and 17 percent admitting to regular use ... ‘Yes to Life,’ volunteers from the Church of Scientology of ... information about drugs, to help reverse this alarming trend. , ... Say ‘Yes’ to Life,” volunteers have distributed 40,000 copies of ...
(Date:8/1/2014)... the University of California, San Diego School of Medicine ... chili peppers produces chronic activation of a receptor ... reaction that ultimately reduces the risk of colorectal tumors. ... 2014 issue of The Journal of Clinical Investigation ... was originally discovered in sensory neurons, where it acts ...
(Date:8/1/2014)... regulating appetite and whole-body metabolism. A protein known as ... intake and body weight, but the identity of the ... A new study in the Journal of Clinical ... of neuron known as pro-opiomelanocortin (POMC) neurons is critical ... Diano and colleagues at Yale University School of Medicine ...
(Date:8/1/2014)... Bronson Gray HealthDay Reporter FRIDAY, ... work in manufacturing jobs may have significantly less endurance than those ... of 32 people -- half were obese, half were of normal ... were about 60 percent longer. Obesity also was associated with ... Being older -- 50 to 65 years of age -- ...
(Date:8/1/2014)... The U.S. Food and Drug Administration announced on Friday ... fight type 2 diabetes. Jardiance (empagliflozin) "can ... to control blood sugar levels in the overall management ... of Drug Evaluation II in the FDA,s Center for ... The FDA also recommended that Jardiance be used ...
Breaking Medicine News(10 mins):Health News:Addressing a Serious Issue Affecting German Teens 2Health News:Pepper and halt: Spicy chemical may inhibit gut tumors 2Health News:Obesity Might Slow You Down at Work 2Health News:Obesity Might Slow You Down at Work 3Health News:FDA Approves New Type 2 Diabetes Drug 2
... standards for elder care in nursing homes are the only ... to prevent serious safety violations, according to a new study ... ,The majority of the nation's elderly and disabled in ... national recommendations for safe care, the study found. While no ...
... approved Torisel (temsirolimus) for the treatment of a certain type ... Torisel was approved based on a study that showed use ... carcinoma. The drug is an enzyme inhibitor, a protein that ... ,'We have made significant advances in the battle against kidney ...
... The National Aeronautics and Space Administration (NASA) has ... disasters.,In fact it goes further than others and ... to push Earth past "critical tipping points" with "dangerous ... by NASA and the Columbia University Earth Institute appears ...
... might be the brand ambassadors of India. But they could ... happened in the case of Thirumurthy Nakka Boomaiah , ... of Tamil Nadu. ,He has been sentenced to ... a flight from London to Philadelphia and assaulting flight attendants. ...
... rubber combined with sulphur to improve its overall strength ... is difficult to reform and reuse old tyres. The ... a landfill, a process that releases heavy metals and other ... David Isaac and colleagues at Swansea University, UK, have shown ...
... technology is expected to help physicians better classify breast ... by the FDA that allows doctors to measure ... new technique may significantly reduce the need for biopsies. ... percent of biopsies turn up positive for cancer. ...
Cached Medicine News:Health News:Policy Changes Have Direct Effect on Nursing Home Care 2Health News:Policy Changes Have Direct Effect on Nursing Home Care 3Health News:FDA: New Drug for Advance Kidney Cancer 2Health News:Global Warming Disaster Closer Than Thought, Says NASA 2Health News:Global Warming Disaster Closer Than Thought, Says NASA 3Health News:Indian Engineer Sentenced for Groping Women During Flight 2
... The wrap frame is constructed of ... while minimizing potential breakage. The molded ... a full saddle bridge to distribute weight ... peripheral vision with leaded glass side shields. ...
... Constructed of optical steel base ... overlay. Comes with custom fitted ... create a seal to the ... from oblique angle exposure. Includes ...
... protection Properly manufactured radiation protective eyewear ... Our high quality frames and materials offer ... weight. Our lenses are made of Schott ... industry standards. Most Pulse Glasses are offered ...
... frames are designed with the safety and comfort ... Schott RS-520 (also called SF-6) leaded glass, the ... meet standards, as set for optical clarity, visible ... our eyewear is protecting your eyes, it also ...
Medicine Products: